CPDR Education and Training
Post-doctoral fellows with M.D. or Ph.D. degrees from the United States and other countries actively participate in the research program and receive state-of-the-art training in basic and translational aspects of cancer research by focusing on prostate cancer. The CPDR is proud of the excellent career advancement that the CPDR trainees have demonstrated. Up to this point, thirty postdoctoral fellows have participated in our program.
Education and Training Opportunities for Graduate Students (M.P.H., Ph.D.) and Medical Students (M.D.) of Uniformed Services University of the Health Sciences (USU)
The CPDR offers opportunities for long-term and short-term training of graduate and medical students at USU. Graduate students undertake original research projects focusing on molecular biology, genetics and translational research focusing on prostate cancer. Three graduate students and several medical students have participated so far in the CPDR laboratory projects. One USU-Molecular and Cell Biology Program student completed his Ph.D. thesis at CPDR. One MPH student from the LAM completed his thesis at CPDR.
CPDR POST DOCTORAL FELLOWS 1991 - PRESENT
|Jaya Gaddipati, Ph.D||(1991-1994)|
|Axel Heidenreich, MD||(1994-1995)|
|Kekule Asgari, Ph.D||(1994-1998)|
|Linda Xu, MD||(1995-1999)|
|Chun Ling Gao, MD||(1997-2002)|
|Wei Zhang, Ph.D (CPDR & AFIP)||(1998-2002)|
|Takehiko Segawa, MD, Ph.D||(1999-2002)|
|Keiichiro Nakamura, MD, Ph.D||(1997-2001)|
|Yutaka Yasunaga, MD, Ph.D||(2000-2001)|
|Sudhir Rawal, MBBS, MS||(2000-2002)|
|Yongpeng Gu, MD, Ph.D||(2000-2006)|
|Kala Prasanna, Ph.D||(2002-2006)|
|Syed Shaheduzamman, Ph.D||(2002-2004)|
|Chen Sun, MD, Ph.D||(2003-2006)|
|Aijun Liu, MD||(2003-2005)|
|Lionel Banez, MD||(2003-2005)|
|Xiaoqin Fu, Ph.D||(2003-2006)|
|Anu Vishwanath, MD||(2003-2004)|
|Bungo Furusato, Ph.D||(2003-2004)|
|Kee-Hong Kim, BTech, Ph.D||(2004-2006)|
|Katsuaki Masuda, MD, Ph.D||(2004-2007)|
|Govindan Vaidyanathan, Ph.D||(2004-2007)|
|Jun Miki, PhD||(2004-2007)|
|Hongzhen Li, PhD||(2007-2009)|
|Ahmed Mohamed, MD, Ph.D||(2006-2009)|
|Ying Hu, MD.PhD||(2006-2009)|
|Shashwat Sharad, Ph.D||(2009-Present)|
|Shiela Macalindong, MD||(2010-2012)|
|Kristen Nickens, Ph.D||(2010-2013)|
|Nicolas Griner, Ph.D||(2011-2013)|
|Anshu Rastiogi, Ph.D||(2011-Present)|
|Jocelyn Lee, PhD., MPH||(2012-Present)|
|Allissa Dillman, Ph.D||(2014-Present)|
|Indu Kohaar, Ph.D||(2014-Present)|
|Charles Xavier, Ph.D||(2014-Present)|
Quarterly Guest Speakers
Dr. Philip Arlen
National Cancer Institute
Topic: "Prostate Cancer: An Overview and Update of Novel Treatment Modalities"
There have been remarkable advances in the therapy for prostate cancer over the past decade. We will be discussing these advances as well as new treatment options in clinical trials.
Date: Thursday 5 May 2016
Location: Walter Reed National Military Medical Center (America Building, 2nd floor, Room 2525) and Fort Belvoir Community Hospital (via video teleconference in Oaks Pavilion, 1st floor, Room 332).
Read the MAY 2016 WRNMMC UsToo! Newsletter
February 2, 2016
CPDR Urology Residents Take Top Awards at 2016 James C. Kimbrough Urological Seminar
Urology Residents conducting research at The Center for Prostate Disease Research (CPDR), Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center presented their research at the Residents Competition category of the James C. Kimbrough Urological Seminar, San Diego, 2016.
January 11, 2016
A Novel Gene Alteration Associates with Aggressive Prostate Cancer in African American Men
The USU, Walter Reed-Bethesda and JPC collaborative team, through comprehensive evaluations of matched cohorts of African American and Caucasian American prostate cancers, previously established a higher frequency of ERG alterations in Caucasians (50-70%) and its significantly lower frequency in African Americans (20-25%). These intriguing observations actually provided the rational for the current study focusing on whole genome evaluations of prostate cancers from these two patient populations.